Acrivon Therapeutics(ACRV.US)

Last Updated 19:00:00 ET
longbridge loading

Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock

Simplywall·
US
ACRV
+8.13%
US
IBB
+1.81%
US
PBE
+1.37%
Simplywall·
US
ACRV
+8.13%
US
IBB
+1.81%
US
PBE
+1.37%

Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy

Tip Ranks·
US
ACRV
+8.13%
US
XBI
+3.49%
US
BBH
+0.68%
Tip Ranks·
US
ACRV
+8.13%
US
XBI
+3.49%
US
BBH
+0.68%

Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer

Tip Ranks·
US
ACRV
+8.13%
US
XLV
-0.25%
US
BIB
+4.36%
Tip Ranks·
US
ACRV
+8.13%
US
XLV
-0.25%
US
BIB
+4.36%

Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M

TradingView·
US
ACRV
+8.13%
US
PBE
+1.37%
US
BBH
+0.68%
TradingView·
US
ACRV
+8.13%
US
PBE
+1.37%
US
BBH
+0.68%

Acrivon Therapeutics Q1 Loss Narrows

Fidelity·
US
ACRV
+8.13%
Fidelity·
US
ACRV
+8.13%

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Unusual Whales·
US
ACRV
+8.13%
Unusual Whales·
US
ACRV
+8.13%
© 2026 Longbridge｜Disclaimer